48
5 th World Psoriasis & Psoriatic Arthritis Conference 2018
ment 2 . An interim analysis at week 80 demonstrated the continua-
tion of improvement in nail psoriasis for all efficacy parameters.
The effect was sustained through 2.5 years with a large mean
NAPSI improvement from baseline (BL) of −73.3% and −63.6%
with secukinumab 300 and 150 mg, respectively (as observed).
Secukinumab demonstrated sustained reductions (improvements)
in total mean NAPPA (Nail Assessment in Psoriasis and Psoria-
tic Arthritis) QoL scores from BL to 2.5 years by −52.4% and
−18.1%, and 70.2% and 71.0% of subjects achieved a weighted
NAPPA-PBI (Patient Benefit Index) global score of ≥2 (at least
moderate benefits) with secukinumab 300 and 150 mg, respec-
tively (LOCF). Subjects showed considerable improvements in
EQ-5D (EuroQOL 5-Dimension Health Status Questionnaire)
compared with BL reporting decreased pain and discomfort. The
safety profile was consistent with that observed in previous phase
3 trials of psoriasis and PsA.
Conclusions: TRANSFIGURE is the first large, randomised con-
trolled trial to report long-term results in subjects with nail psoria-
sis. Secukinumab demonstrated strong sustainability of clinically
meaningful efficacy, large QoL improvement and a favourable
safety profile up to 2.5 years in this challenging form of psoriasis.
This investigation was sponsored by Novartis Pharma AG, Basel,
Switzerland.
References:
Baran R. Dermatology. 2010; 221 Suppl 1:1–5.
Reich K. Ann Rheum Dis. 2016;75:603.
P117
THE OBESITY AND PREVALENCE PSORIATIC
ARTHRITIS IN PATIENTS WITH PLAQUE PSORIASIS:
DERMATOLOGICAL REAL-SETTING DATA
Maria Chamurlieva, Tatiana Korotaeva
N.A.Nasonova Research Institute of Rheumatology
Background: Psoriasis (PsO) is a chronic inflammatory disease,
which can be associated with the obesity. A link between body
mass index (BMI) and psoriatic arthritis (PsA) has been found
recently. But there is limited data about this association in Russian
population and from real-world data.
Objective:To study the incidence of PsA in PsO patients (pts)
with/without obesity.
Methods: 103 pts (male-47/female-56) with different forms of
plaque PsO, mean age 44 ± 13.69 years (yrs.), mean PsO duration
10.7 ± 10.2 yrs., mean PASI 15.39 ± 12.51 were included. 61 out of
103 pts with PsO (59.2%) had psoriatic arthritis (PsA) by CASPAR
criteria. In all pts BMI was calculated. If the BMI was more than
30 it was regarded as obesity. M ± m, %, t-test were peformed. All
p < 0.05 were considered to indicate statistical significance.
Results: The overweight in both groups of pts with PsO and PsA
was not significantly different: in 30 pts without PsA and in 48
with PsA, 71.4% and 78.7% respectively. However, there was a
significant difference in the frequency of PsA in the group of pts
with a BMI = 30–35 (obesity 1 degree). Thus, it was more than 4
times higher the pts with PsA, compared with pts without PsA - 19
and 4 pts (31.2% vs. 9.5%) respectively (p = 0.06).
Conclusion: There is a higher incidence of PsA in PsO pts with
obesity. It should be taken into account during choice of treatment
and evaluation of efficiency of therapy in real-world dermatologi-
cal setting. Russian population – based studies are needed.
P118
DIAGNOSIS OF PSORIATIC ARTHRITIS IN
PATIENTS WITH MODERATE TO SEVERE
CHRONIC PLAQUE PSORIASIS TREATED WITH
SECUKINUMAB VS. OTHER TREATMENTS IN THE
PURE REGISTRY: INDICATION OF SELECTION
PREFERENCES AND UNDERDIAGNOSIS
www.medicaljournals.se/acta
Kim Papp 1 , Melinda Gooderham 2 , Jennifer Beecker 3 , Charles Lyn-
de 4 , Isabelle Delorme 5 , Ignacio Dei-Cas 6 , Emmanouil Rampaka-
kis 7 , Lenka Rihakova 8 , Shamiza Hussein 8 , Antonio Vieira 8
K Papp Clinical Research and Probity Medical Research, Waterloo, ON,
SKiN Center for Dermatology, Queen’s University and Probity Medical
Research, Peterborough, ON, 3 University of Ottawa, Division of Dermato-
logy, Ottawa, ON, 4 Lynde Institute for Dermatology, University of Toronto
and Probity Medical Research, Markham, ON, 5 Dr. Isabelle Delorm Inc,
Drummondville, QC, Canada, 6 Facultad de Medicina de la Universidad de
Buenos Aires, Buenos Aires, Argentina, 7 JSS Medical, Saint-Laurent, QC,
8
Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada
1
2
Introduction: Secukinumab (SEC) is a fully human monoclonal
antibody that selectively neutralizes IL-17A, a key cytokine
involved in the development of psoriasis (PsO). SEC has shown
long lasting efficacy and safety in the complete spectrum of PsO
manifestations, including nails, scalp, palms and soles and psoriatic
arthritis (PsA). PURE is an international registry of adult patients
(pts) from Canada and Latin America with moderate to severe PsO
treated with SEC vs other approved therapies (other Tx).
Objectives: To describe and compare the baseline demographic,
disease, and clinical characteristics – specifically, the history of
a PsA diagnosis among PsO pts treated with SEC vs other Tx.
Methods: Approximately 2,500 adult pts (1:1 ratio, SEC: other Tx)
will be recruited. A decision regarding treatment must have been
reached prior to enrollment. The independent-samples and Chi-
square tests were used for continuous and categorical variables,
respectively, for treatment group comparison.
Results: As of Nov 27, 2017, 1032 pts (397 SEC vs 635 other Tx)
had been e